Your browser doesn't support javascript.
Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study.
Chan, Edward Wai Wa; Leung, Miriam Tim Yin; Lau, Lauren Ka Wun; Leung, Janice; Lum, Dawn; Wong, Rosa Sze-Man; Li, Xue; Chui, Celine Sze Ling; Wan, Eric Yuk Fai; Wong, Carlos King Ho; Chan, Esther Wai Yin; Ip, Patrick; Wong, Ian Chi Kei; Lai, Francisco Tsz Tsun.
  • Chan EWW; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China.
  • Leung MTY; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
  • Lau LKW; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
  • Leung J; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China.
  • Lum D; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
  • Wong RS; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
  • Li X; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China; Department of
  • Chui CSL; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China; School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong,
  • Wan EYF; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China; Department of
  • Wong CKH; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China.
  • Chan EWY; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China.
  • Ip P; Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
  • Wong ICK; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China; Research Depar
  • Lai FTT; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; Laboratory of Data Discovery for Health (D²4H), Hong Kong Science and Technology Park, Hong Kong, China. Electronic add
Int J Infect Dis ; 116: 47-50, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1587613
ABSTRACT

OBJECTIVES:

Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant.

METHODS:

We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected.

RESULTS:

Results from the generalized mixed model showed that compared with adults aged 18 to 59 years, older adults aged 60 years or above had a lower risk of adverse reactions and adolescents aged 12 to 17 years had a moderately higher risk.

CONCLUSIONS:

Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Child / Humans / Middle aged / Young adult Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2021.12.354

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Child / Humans / Middle aged / Young adult Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2021.12.354